Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Instagram Outage Disrupts Thousands of U.S. Users 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
GAITHERSBURG, Md., Nov. 01, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) will release its financial results for the third quarter on Monday, November 7, 2016 and host a conference call at 5:00 pm (Eastern Time). In the press release and on the conference call, the Company will discuss its financial results for the quarter and year-to-date periods of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: |
| Dial in number: (855) 766-6521 |
| International dial in: (262) 912-6157 |
| Conference ID: 29486767 |
| Live Webcast Information: |
| Visit http://edge.media-server.com/m/p/89rbd7rh/lan/en for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website www.emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 [email protected]
